Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (61-70 of 377) with videos related to

Pageof 38
Sort By:
Breast Care (Basel, Switzerland)|December 3, 2011
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and ConceptsCarsten Denkert, Bruno Valentin Sinn, Yasmin Issa, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 22, 2016
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in GermanyJosef Rüschoff, Annette Lebeau, Hans Kreipe, et al.
Breast (Edinburgh, Scotland)|January 10, 2020
Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in GermanyJosef Rüschoff, Annette Lebeau, Peter Sinn, et al.
Anticancer Research|July 26, 2007
The risk of non-sentinel metastases in primary breast cancerIngo G Bauerfeind, Steffen Kahlert, Isabelle Himsl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 26, 2015
Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization dataOliver C Stoss, Andreas Scheel, Iris Nagelmeier, et al.
Clinical Pharmacokinetics|June 23, 2026
Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast CancerYan Ji, Craig Wang, Francois Pierre Combes, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2009
What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?Matti Aapro, Agustí Barnadas, Robert C Leonard, et al.
Anticancer Research|August 15, 2002
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate)Peter Schmid, Michael Untch, Diethelm Wallwiener, et al.
Breast Cancer Research and Treatment|June 29, 2018
The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancerMeghan Brennan, Paul Gass, Lothar Häberle, et al.
Onkologie|March 15, 2013
Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatmentMaike de Wit, Petra Ortner, Hans-Peter Lipp, et al.
Pageof 38

Showing results (61-70 of 377) with videos related to

Sort By:
Pageof 38
Breast Care (Basel, Switzerland)|December 3, 2011
Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and ConceptsCarsten Denkert, Bruno Valentin Sinn, Yasmin Issa, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 22, 2016
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in GermanyJosef Rüschoff, Annette Lebeau, Hans Kreipe, et al.
Breast (Edinburgh, Scotland)|January 10, 2020
Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in GermanyJosef Rüschoff, Annette Lebeau, Peter Sinn, et al.
Anticancer Research|July 26, 2007
The risk of non-sentinel metastases in primary breast cancerIngo G Bauerfeind, Steffen Kahlert, Isabelle Himsl, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 26, 2015
Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization dataOliver C Stoss, Andreas Scheel, Iris Nagelmeier, et al.
Clinical Pharmacokinetics|June 23, 2026
Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast CancerYan Ji, Craig Wang, Francois Pierre Combes, et al.
European Journal of Cancer (Oxford, England : 1990)|August 4, 2009
What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?Matti Aapro, Agustí Barnadas, Robert C Leonard, et al.
Anticancer Research|August 15, 2002
Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate)Peter Schmid, Michael Untch, Diethelm Wallwiener, et al.
Breast Cancer Research and Treatment|June 29, 2018
The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancerMeghan Brennan, Paul Gass, Lothar Häberle, et al.
Onkologie|March 15, 2013
Management of cytotoxic extravasation - ASORS expert opinion for diagnosis, prevention and treatmentMaike de Wit, Petra Ortner, Hans-Peter Lipp, et al.
Pageof 38